Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysisWon‐Mook Choi, Young‐Suk Lim, Dae Won Jun et al.|Journal of Hepatology|2022Cited by 62
Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patientsWon‐Mook Choi, Young‐Suk Lim, Terry Cheuk‐Fung Yip et al.|Hepatology|2024Cited by 33
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trialYoung‐Suk Lim, Seungbong Han, Ming‐Lung Yu et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 23
Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort StudyWon‐Mook Choi, Young‐Suk Lim, Terry Cheuk‐Fung Yip et al.|Clinical Gastroenterology and Hepatology|2024Cited by 16
Combination of α‐interferon with lamivudine reduces viral breakthrough during long‐term therapyMyoung Kuk Jang, Dong Jin Suh, Young–Hwa Chung et al.|Journal of Gastroenterology and Hepatology|2004Cited by 15